Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Rapt Therapeutics Inc
(NQ:
RAPT
)
2.230
+0.110 (+5.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rapt Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Dow Rebounds; Nasdaq Drops Triple Digits
February 20, 2024
Nvidia stock is sliding ahead of tomorrow's earnings report
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Nasdaq Down 1%; Capital One Set To Buy Discover
February 20, 2024
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.05% to 38,607.53 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 20, 2024
Via
Benzinga
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
February 20, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Recap: RAPT Therapeutics Q3 Earnings
November 13, 2023
Via
Benzinga
Analyst Ratings for RAPT Therapeutics
September 14, 2023
Via
Benzinga
The Latest Analyst Ratings for RAPT Therapeutics
August 09, 2023
Via
Benzinga
Analyst Ratings for RAPT Therapeutics
June 05, 2023
Via
Benzinga
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
February 13, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Analyst Expectations for RAPT Therapeutics's Future
May 12, 2023
Via
Benzinga
Recap: RAPT Therapeutics Q1 Earnings
May 11, 2023
Via
Benzinga
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
November 27, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023
Company maintains strong cash position of $184.8 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
November 03, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
November 01, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
October 18, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
September 27, 2023
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
September 14, 2023
Via
Benzinga
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
August 30, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
August 11, 2023
Company maintains strong cash position of $205 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
August 09, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
June 15, 2023
Via
Benzinga
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
June 07, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
May 25, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports First Quarter 2023 Financial Results
May 11, 2023
Company maintains strong cash position of $231.6 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
May 03, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 17, 2023
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.